Mounjaro and Wegovy contain different active molecules and carry separate approved indications from the United States Food and Drug Administration. Mounjaro is tirzepatide approved for type 2 diabetes, whereas Wegovy is semaglutide approved for chronic weight management. Each molecule has an approved sibling brand for the alternate therapeutic purpose, meaning a comparison of these two brands spans two different approved indications rather than identical clinical roles.
At Longevity Benchmark, we review clinical trial publications and manufacturer prescribing documents to clarify how these therapies compare in research and regulation. A direct head-to-head clinical trial evaluating Mounjaro against Wegovy at their specific approved target doses has never been published. Understanding the documented evidence requires examining how each active molecule performed across dedicated trials in diabetes and obesity.
The Verdict
Mounjaro (tirzepatide) vs Wegovy (semaglutide), Side by Side
| Attribute | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Active molecule | Tirzepatide | Semaglutide |
| Receptor target | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Approved use category | Type 2 diabetes | Chronic weight management |
| Sibling brand for alternate use | Zepbound (chronic weight management) | Ozempic (type 2 diabetes) |
| Closest head-to-head diabetes trial | SURPASS-2 (evaluated against semaglutide 1 mg, which is below Wegovy target doses) | SURPASS-2 (evaluated at a 1 mg diabetes dose rather than weight-management doses) |
| Published cardiovascular outcomes trial | No published cardiovascular outcomes trial is available to cite here | SELECT: primary cardiovascular end point hazard ratio 0.80 (95% CI 0.72 to 0.90) |
| Most common adverse events | Gastrointestinal events including nausea, diarrhea, and vomiting | Gastrointestinal events including nausea, diarrhea, and vomiting |
| Administration method | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
Two Molecules, Two Approved Indications
Mounjaro and Wegovy represent two distinct active pharmaceutical ingredients approved by regulatory authorities for entirely different therapeutic indications.
The active ingredient in Mounjaro is tirzepatide, manufactured by Eli Lilly as a dual GIP and GLP-1 receptor agonist. The active ingredient in Wegovy is semaglutide, manufactured by Novo Nordisk as a GLP-1 receptor agonist. Both medications are formulated as once-weekly subcutaneous injections. However, the United States Food and Drug Administration approved Mounjaro for type 2 diabetes, whereas Wegovy is approved for chronic weight management.
This regulatory divide means comparing Mounjaro directly to Wegovy pairs a diabetes therapy against a weight-management therapy. When clinicians and patients discuss these medications, confusion frequently arises because both produced weight reduction in the trials cited here. Even so, the specific brand names reflect distinct regulatory filings, approved labeling, and targeted clinical indications.
The Four Brand Map of Semaglutide and Tirzepatide
Four distinct commercial brand names encompass the injectable formulations of semaglutide and tirzepatide currently marketed in the United States.
Each pharmaceutical manufacturer developed two separate brand identities for its respective molecule to address type 2 diabetes and chronic weight management independently. Novo Nordisk markets semaglutide for type 2 diabetes under the brand name Ozempic and for chronic weight management under the brand name Wegovy. Novo Nordisk also manufactures Rybelsus, an oral tablet formulation of semaglutide approved for type 2 diabetes. Eli Lilly markets tirzepatide for type 2 diabetes under the brand name Mounjaro and for chronic weight management under the brand name Zepbound.
Selecting the appropriate published evidence requires consulting the exact comparison aligned with a specific clinical scenario. The dedicated comparison of Zepbound vs Wegovy evaluates the two agents approved specifically for chronic weight management. The analysis of Ozempic vs Wegovy addresses the same active molecule across its two approved indications. The biological distinctions between the underlying active ingredients are detailed in our guide to semaglutide vs tirzepatide.
| Active Molecule | Brand Name | Approved Indication | Manufacturer |
|---|---|---|---|
| Semaglutide | Ozempic | Type 2 diabetes (injectable) | Novo Nordisk |
| Semaglutide | Wegovy | Chronic weight management (injectable) | Novo Nordisk |
| Semaglutide | Rybelsus | Type 2 diabetes (oral tablet) | Novo Nordisk |
| Tirzepatide | Mounjaro | Type 2 diabetes (injectable) | Eli Lilly |
| Tirzepatide | Zepbound | Chronic weight management (injectable) | Eli Lilly |
Glycemic and Weight Data From the SURPASS 2 Trial
The SURPASS-2 clinical trial provides the primary published direct comparison between tirzepatide and semaglutide in patients with type 2 diabetes.
Published in The New England Journal of Medicine in 2021 and funded by Eli Lilly, SURPASS-2 was a 40-week, open-label trial that enrolled 1,879 adult participants with type 2 diabetes. At baseline, the study cohort had a mean glycated hemoglobin (HbA1c) of 8.28 percent, a mean age of 56.6 years, and a mean body weight of 93.7 kilograms. Investigators randomized participants to receive once-weekly subcutaneous injections of tirzepatide at trial arm doses of 5 mg, 10 mg, or 15 mg, or semaglutide at a trial arm dose of 1 mg.
Reductions in HbA1c from baseline in SURPASS-2 were 2.01 percentage points with tirzepatide 5 mg, 2.24 percentage points with tirzepatide 10 mg, and 2.30 percentage points with tirzepatide 15 mg, compared to a reduction of 1.86 percentage points with semaglutide 1 mg. The estimated treatment differences between tirzepatide and semaglutide were -0.15 percentage points (95% CI -0.28 to -0.03, P=0.02) for 5 mg, -0.39 percentage points (95% CI -0.51 to -0.26, P<0.001) for 10 mg, and -0.45 percentage points (95% CI -0.57 to -0.32, P<0.001) for 15 mg. Body weight reductions showed treatment differences of -1.9 kg, -3.6 kg, and -5.5 kg favoring the respective tirzepatide arms over semaglutide (P<0.001 for all comparisons).
A critical clinical caveat governs the interpretation of SURPASS-2 when considering Wegovy. The semaglutide arm in SURPASS-2 was 1 mg, a type 2 diabetes dose. Wegovy's weight-management dose is higher, so SURPASS-2 does not test Wegovy as prescribed.
Weight Management Evidence in the SURMOUNT 5 Trial
The SURMOUNT-5 clinical trial represents the first published head-to-head comparison of tirzepatide and semaglutide specifically designed around weight-management formulations.
Published in The New England Journal of Medicine in 2025 and funded by Eli Lilly, SURMOUNT-5 was a phase 3b, open-label trial involving 751 adults who had obesity without type 2 diabetes. Participants were randomized in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) once weekly for 72 weeks.
At week 72, the least-squares mean percentage change in body weight in SURMOUNT-5 was -20.2 percent (95% CI -21.4 to -19.1) with tirzepatide compared to -13.7 percent (95% CI -14.9 to -12.6) with semaglutide, yielding a statistically significant difference (P<0.001). Mean waist circumference decreased by 18.4 centimeters in the tirzepatide group compared to 13.0 centimeters in the semaglutide group (P<0.001). Related analyses on body composition and adipose tissue changes are detailed in our overview of visceral fat.
While SURMOUNT-5 evaluated the active molecules at doses corresponding to weight-management labeling, it did not test Mounjaro under its approved diabetes indication. The trial enrolled participants without diabetes and utilized dosing protocols aligned with Zepbound and Wegovy. The exact weight-management pairing is Zepbound vs Wegovy.
Cardiovascular Outcomes Evidence and the SELECT Trial
Cardiovascular outcomes research establishes a documented clinical evidence base for semaglutide that currently lacks an identical published counterpart for tirzepatide.
Published in The New England Journal of Medicine in 2023 and funded by Novo Nordisk, the SELECT trial evaluated semaglutide at a weekly dose of 2.4 mg in 17,604 patients aged 45 years or older. All enrolled participants had preexisting cardiovascular disease and a body mass index of 27 or greater, but none had diabetes. Over a mean follow-up duration of 39.8 months, the primary cardiovascular end point occurred in 6.5 percent of patients in the semaglutide group compared to 8.0 percent of patients in the placebo group, corresponding to a hazard ratio of 0.80 (95% CI 0.72 to 0.90, P<0.001).
Permanent treatment discontinuation attributable to adverse events occurred in 16.6 percent of semaglutide participants compared to 8.2 percent of placebo participants in the SELECT trial (P<0.001).
No published cardiovascular outcomes trial for tirzepatide is available to cite here, meaning cardiovascular outcomes between Mounjaro and Wegovy cannot be evaluated on equal empirical terms. Future trial completions may alter this comparison, but current published literature contains established cardiovascular endpoint data exclusively for the semaglutide 2.4 mg arm of SELECT.
Reported Adverse Events and Official Boxed Warnings
Gastrointestinal symptoms constitute the primary adverse events documented across clinical trials evaluating both tirzepatide and semaglutide.
In the SURPASS-2 trial comparing tirzepatide to semaglutide 1 mg, nausea was reported in 17 to 22 percent of tirzepatide patients across dose tiers and in 18 percent of semaglutide patients. Diarrhea occurred in 13 to 16 percent of tirzepatide patients and 12 percent of semaglutide patients, while vomiting occurred in 6 to 10 percent of tirzepatide patients and 8 percent of semaglutide patients. Most gastrointestinal events across both study arms were mild to moderate in severity and arose predominantly during the dose-escalation phase. For comprehensive timelines regarding symptom onset, refer to our guide on semaglutide side effects timeline.
Clinically significant hypoglycemia, defined as blood glucose below 54 mg/dL, was documented in SURPASS-2 among 0.6 percent of participants receiving tirzepatide 5 mg, 0.2 percent receiving 10 mg, 1.7 percent receiving 15 mg, and 0.4 percent receiving semaglutide 1 mg. Serious adverse events were recorded in 5 to 7 percent of tirzepatide participants across doses and in 3 percent of semaglutide participants. Broader safety reporting across related trials is compiled in our review of semaglutide side effects.
The approved United States prescribing information for Mounjaro, Zepbound, Ozempic, and Wegovy contains an identical boxed warning regarding thyroid C-cell tumors observed in rodent carcinogenicity studies. Detailed contraindications and safety parameters are set forth in the full prescribing information documents for Mounjaro and Wegovy.
Clinical Evidence Limits
Published clinical literature leaves several practical parameters unaddressed when evaluating Mounjaro alongside Wegovy.
Scientific trials do not publish individualized pricing, health plan coverage rules, copay card eligibility, or pharmacy inventory levels, all of which vary across commercial insurers and geographic regions. Furthermore, clinical trials provide strict protocol-driven escalation schedules rather than flexible real-world adaptations, and no published trial examines compounded formulations against approved brand-name products. Considerations regarding compounded products are detailed in our reviews of compounded vs brand semaglutide and compounded vs brand tirzepatide.
Diagnostic testing considerations are covered in our guides on A1c vs fasting glucose and fasting insulin. Documented factors behind a stalling weight-loss trajectory are covered in our review of the weight loss plateau.
Frequently Asked Questions
Is Mounjaro approved for weight loss?
No, Mounjaro is not approved by the Food and Drug Administration for weight loss. Mounjaro is an injectable formulation of tirzepatide approved for type 2 diabetes. Its manufacturer, Eli Lilly, markets tirzepatide for chronic weight management under a separate brand name, Zepbound. While clinical trials of Mounjaro documented substantial weight loss among participants with type 2 diabetes, regulatory approval for weight management belongs exclusively to Zepbound.
Is Wegovy approved for type 2 diabetes?
No, Wegovy is not approved by the Food and Drug Administration for the treatment of type 2 diabetes. Wegovy is an injectable formulation of semaglutide approved specifically for chronic weight management. Novo Nordisk markets semaglutide for type 2 diabetes under two different brand names: Ozempic as a once-weekly subcutaneous injection and Rybelsus as a daily oral tablet. Each brand name reflects a distinct regulatory filing, approved labeling, and targeted clinical indication.
Which is more effective, Mounjaro or Wegovy?
No published clinical trial has compared Mounjaro directly against Wegovy at their approved target doses, making a definitive comparison unavailable in the medical literature. In the SURPASS-2 trial in type 2 diabetes, tirzepatide produced greater reductions in HbA1c and body weight than semaglutide 1 mg, but that trial used a 1 mg type 2 diabetes dose, and Wegovy's weight-management dose is higher. Conversely, in the SURMOUNT-5 trial in obesity, tirzepatide produced greater weight loss than semaglutide 2.4 mg, but that trial evaluated the weight-management formulations rather than Mounjaro. Effectiveness depends entirely on the clinical outcome measured and the specific condition being treated.
Is Mounjaro the same as Zepbound?
Mounjaro and Zepbound share the same active pharmaceutical ingredient, tirzepatide, and are manufactured by Eli Lilly as once-weekly subcutaneous injections. However, they carry different approved indications and distinct prescribing labels. The Food and Drug Administration approved Mounjaro for type 2 diabetes. In contrast, Zepbound is approved for chronic weight management. The two brands have separate regulatory approvals, commercial packaging, and prescribing information documents.
Is Wegovy the same as Ozempic?
Wegovy and Ozempic contain the identical active pharmaceutical ingredient, semaglutide, and are manufactured by Novo Nordisk as once-weekly subcutaneous injections. Despite sharing the same active molecule, they are approved for different medical purposes. Ozempic is approved for type 2 diabetes and Wegovy for chronic weight management. Dosing for either brand is in its own prescribing information rather than on this page. The two brands carry distinct packaging, approved indications, and clinical guidelines.
Has Mounjaro been compared directly against Wegovy?
No head-to-head clinical trial evaluating Mounjaro directly against Wegovy has ever been published. The closest published head-to-head evidence comes from two separate trials evaluating different doses and populations. The SURPASS-2 trial compared tirzepatide to semaglutide in type 2 diabetes, but it used semaglutide at a 1 mg dose rather than Wegovy target doses. The SURMOUNT-5 trial compared the molecules at weight-management doses up to 15 mg of tirzepatide and 2.4 mg of semaglutide, but it enrolled participants with obesity who did not have diabetes. Direct trial data comparing the two specific brand names under their respective approved labels does not exist.
Do Mounjaro and Wegovy have the same side effects?
Both medications share a similar adverse event profile dominated by gastrointestinal symptoms that occur primarily during dose escalation. In clinical trials, the most frequently reported events for both tirzepatide and semaglutide were nausea, diarrhea, and vomiting, with most episodes rated mild to moderate in severity. Serious adverse events and hypoglycemia occurred at low rates across published studies. In addition, the official prescribing information for both Mounjaro and Wegovy contains a boxed warning concerning thyroid C-cell tumors identified in rodent studies. Full safety profiles and contraindications are detailed in each product's official prescribing information.
Does either one have proven heart benefits?
Wegovy has established cardiovascular outcome trial data from the SELECT study, whereas an equivalent published trial for tirzepatide is not available to cite here. In the SELECT trial, semaglutide 2.4 mg administered to patients with preexisting cardiovascular disease and overweight or obesity without diabetes demonstrated a hazard ratio of 0.80 (95% CI 0.72 to 0.90) for the primary cardiovascular end point compared to placebo over a mean follow-up of 39.8 months. No published cardiovascular outcomes trial evaluates Mounjaro on comparable empirical terms, leaving semaglutide as the only molecule between the two with completed cardiovascular endpoint trial evidence.